Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06001073

Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics

The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Cardiovascular and cerebrovascular diseases refer to ischemic and hemorrhagic diseases of the heart, brain and body tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc. It is one of the major public health problems in the world. The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are regularly visited and followed up in the appropriate patient; department.
  • All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases:
  • coronary artery disease group;
  • arrhythmia group;
  • heart valve disease group;
  • aortic dissection group;
  • cardiac masses group;
  • myocarditis group;
  • hypertension group;
  • cardiomyopathy group;
  • structural heart disease group;
  • ischemic cerebrovascular disease group;
  • hemorrhagic cerebrovascular disease group;
  • intracranial space occupying lesion group.

Exclusion criteria

  • Age <3 years or >80 years old;
  • Pregnant and lactating women;
  • The patient declined to provide informed consent to participate in the study;
  • None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.

Treatment and study plan

Observational; No Interventions were given.

Other

Observational; No Interventions were given.

Primary outcomes

  1. Change of MACCE

    Time frame: Through study completion, up to 5 years.

    Major adverse cardiovascular and cerebrovascular events, a composite of all-cause mortality, myocardial infarction, coronary revascularization, and stroke.

Secondary outcomes

  1. Change of all-cause mortality

    Time frame: Through study completion, up to 5 years.

    Incidence of patients' death from any cause.

  2. Incidence of myocardial infarction

    Time frame: Through study completion, up to 5 years.

    Changes of serum myocardial zymogram level and ECG were used for diagnosing of myocardial infarction.

  3. Incidence of coronary revascularization.

    Time frame: Through study completion, up to 5 years.

    Incidence of percutaneous coronary intervention or coronary artery bypass grafting.

  4. Incidence of stroke

    Time frame: Through study completion, up to 5 years.

    Stroke were assessed by radiologist using CT scan or other imaging test.

Study contacts

Contact information is provided by the study sponsor or research team.

Gouliang Li

CONTACT

[email protected]

13759982523

Yang Yan

CONTACT

[email protected]

13259882601

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital Xi'an Jiaotong University

Other

Collaborators

  • First Affiliated Hospital of Chongqing Medical University
  • General Hospital of Ningxia Medical University
  • Second Affiliated Hospital of Nanchang University
  • Xi'an Gaoxin Hospital

Registry information

Official study title

Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics (PROSPECT): a National, Multicenter, Retrospective-prospective, Cohort Study

Acronym: PROSPECT

Important dates

Study start
2022
Primary completion
2028
Study completion
2028
First posted
Aug 21, 2023
Registry last updated
Jul 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.